The European Commission has signed an agreement with Cambridge, Mass.-based Moderna for up to 160 million doses of its COVID-19 vaccine candidate, mRNA-1273, which has demonstrated 94.5 percent efficacy in a phase 3 clinical trial.

This marks the sixth advance purchase agreement the EU has signed for a COVID-19 vaccine. It has also struck deals with AstraZeneca, Pfizer/BioNTech, Sanofi/GlaxoSmithKline, Johnson & Johnson and CureVac.

Financial terms of the EU contract were not disclosed, but Moderna CEO Stephane Bancel said the company planned to charge governments between $25 and $37 per dose.